company background image
FRE logo

Fresenius SE KGaA XTRA:FRE Voorraadrapport

Laatste prijs

€32.77

Marktkapitalisatie

€18.5b

7D

-1.2%

1Y

18.6%

Bijgewerkt

19 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Fresenius SE & Co. KGaA

XTRA:FRE Voorraadrapport

Marktkapitalisatie: €18.5b

FRE Overzicht aandelen

Fresenius SE & Co. KGaA, een bedrijf in de gezondheidszorg, levert producten en diensten voor chronisch zieke patiënten. Meer informatie

Beloningen

Verhandeld tegen 63.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 38.96% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 22.2% zal stijgen

Risicoanalyse

Heeft een hoog schuldenniveau


Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
WarrenAI
Based on Analyst Price Targets

Biopharma Innovations And Critical Growth Initiatives Propel Earnings And Margin Expansion

Key Takeaways Strategic initiatives focused on productivity and organic growth are expected to enhance operational efficiency and drive margin expansion. Successful biosimilar launches and market access efforts support sustained revenue growth and improved financial flexibility.
View narrative
€39.99
FV
18.1% undervalued intrinsic discount
3.03%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
13 days ago author updated this narrative
TO
Tokyo
Community Contributor

First comes the pain, then the money.

My main narrative for FRE: What former CEO Mark Schneider blow up to an inefficient giant, will now be cut down by actual CEO Michael Sen and trimmed on efficiency from formally 4 segments FMC (dialyses), Helios (private hospitals), Kabi(Generic & Infusions), Vamed (Projects & Digitalization) only 2 remain: Helios, Kabi, the other will be sold, and the intakes will help to restructure the financial situation under Mark Schneider the Spanish hospitals were acquired, this was a good deal: privat hospital runs well in Spain, because of their good reputation wealthy Latin Americans travel for medical treatments to Spain I focus also on: More equity than debt. Ratio is at 62% (debt/equity).
View narrative
€74.00
FV
55.7% undervalued intrinsic discount
24.16%
Revenue growth p.a.
3users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
4 months ago author updated this narrative

Fresenius SE & Co. KGaA Concurrenten

Fresenius Medical Care

XTRA:FME

€12.2b

SYNLAB

HMSE:SYAB

€2.5b

Siemens Healthineers

XTRA:SHL

€55.1b

Labcorp Holdings

NYSE:LH

US$19.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Fresenius SE KGaA
Historische aandelenkoersen
Huidige aandelenkoers€32.77
52 Week Hoogtepunt€36.24
52 Week Laag€24.32
Bèta1.04
11 maand verandering-2.03%
3 maanden verandering1.64%
1 Jaar Verandering18.65%
33 jaar verandering-7.70%
5 jaar verandering-34.04%
Verandering sinds IPO2,802.59%

Recent nieuws en updates

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Sep 18
Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Aug 19
Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Recent updates

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Sep 18
Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Aug 19
Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jul 15
We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

Jun 12
Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

May 28
At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

May 02
With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Mar 29
Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Mar 13
Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

Feb 06
Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Jan 19
A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Jan 03
Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Nov 28
Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Nov 10
Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Oct 27
Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

Jul 25
Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jun 19
We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Jun 01
At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Apr 18
Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

Mar 13
Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Mar 10
These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Feb 23
Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Feb 08
Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Jan 03
The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Nov 28
These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Oct 23
Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Oct 01
The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Aug 07
Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 20
Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Jul 02
Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

Apr 28
Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Apr 17
At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Apr 02
Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Mar 27
Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Feb 24
Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Rendement voor aandeelhouders

FREDE HealthcareDE Markt
7D-1.2%0.8%-0.2%
1Y18.6%17.2%7.8%

Rendement versus industrie: FRE kwam overeen met de German Healthcare industrie, die het afgelopen jaar een rendement opleverde van 17.2 %.

Rendement versus markt: FRE overtrof de German markt, die het afgelopen jaar een rendement opleverde van 7.8 %.

Prijsvolatiliteit

Is FRE's price volatile compared to industry and market?
FRE volatility
FRE Average Weekly Movement2.5%
Healthcare Industry Average Movement4.0%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.1%
10% least volatile stocks in DE Market2.4%

Stabiele aandelenkoers: FRE heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van FRE is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
1912177,091Michael Senwww.fresenius.com

Fresenius SE & Co. KGaA, een bedrijf in de gezondheidszorg, levert producten en diensten voor chronisch zieke patiënten. Het bedrijf is actief via vier segmenten: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios en Fresenius Vamed. Het segment Fresenius Medical Care biedt producten en diensten voor patiënten met chronisch nierfalen.

Fresenius SE & Co. KGaA Samenvatting

Hoe verhouden de winst en inkomsten van Fresenius SE KGaA zich tot de beurswaarde?
FRE fundamentele statistieken
Marktkapitalisatie€18.46b
Inkomsten(TTM)-€479.00m
Inkomsten(TTM)€22.81b

0.8x

P/S-verhouding

-38.5x

Koers/Winstverhouding

Is FRE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
FRE resultatenrekening (TTM)
Inkomsten€22.81b
Kosten van inkomsten€17.48b
Brutowinst€5.33b
Overige uitgaven€5.81b
Inkomsten-€479.00m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-0.85
Brutomarge23.37%
Nettowinstmarge-2.10%
Schuld/Eigen Vermogen Verhouding60.9%

Hoe presteerde FRE op de lange termijn?

Bekijk historische prestaties en vergelijking